S. Négrier

Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC)

Bernard Escudier, Joaquim Bellmunt, S. Négrier et al. · Journal of Clinical Oncology · 2009 · 88 citations

Surgical Oncology, Avoren Trial, Clinical Endpoint +19

Update of a phase 1 study of intravenous CCI-779 given in combination with interferon-α to patients with advanced renal cell carcinoma

J. W. Smith, Yoo-Joung Ko, Janice P. Dutcher et al. · Journal of Clinical Oncology · 2004 · 56 citations

Renal Pathology, Renal Inflammation, Pharmacotherapy +16

4506 ORAL A large open-label, non-comparative, phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma

J. Thaddeus Beck, Emilio Bajetta, Bernard Escudier et al. · European Journal of Cancer Supplements · 2007 · 37 citations

Urology, Genitourinary Cancer, Medicine +6

TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-α).

Shekar Patil, Robert A. Figlin, Thomas E. Hutson et al. · Journal of Clinical Oncology · 2010 · 34 citations

Sunitinib Pts, Pharmacotherapy, Pre-clinical Pharmacology +22

A LARGE OPEN-LABEL, NON-COMPARATIVE, PHASE III STUDY OF THE MULTI-TARGETED KINASE INHIBITOR SORAFENIB IN EUROPEAN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA

J. Thaddeus Beck, Elena Verzoni, S. Négrier et al. · European Urology Supplements · 2008 · 23 citations

Urology, Genitourinary Cancer, Medicine +6